Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Julia Schüler, Daniel Ewerth, Johannes Waldschmidt, Ralph Wäsch & Monika Engelhardt. (2013) Preclinical models of multiple myeloma: a critical appraisal. Expert Opinion on Biological Therapy 13:sup1, pages S111-S123.
Read now
Read now
Sigurdur Y Kristinsson, Alex R Minter, Neha Korde, Esther Tan & Ola Landgren. (2011) Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Review of Molecular Diagnostics 11:6, pages 593-603.
Read now
Read now
Articles from other publishers (40)
Wen Ling, Sarah K Johnson, Syed J Mehdi, Daisy V Alapat, Michael Bauer, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee & Shmuel Yaccoby. (2023) EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression. Cancers 15:18, pages 4519.
Crossref
Crossref
Daniel García-Sánchez, Alberto González-González, Ana Alfonso-Fernández, Mónica Del Dujo-Gutiérrez & Flor M Pérez-Campo. (2023) Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: Impact on disease progression. World Journal of Stem Cells 15:5, pages 421-437.
Crossref
Crossref
Johannes M. Waldschmidt, Stefan J. Fruttiger, Dagmar Wider, Johannes Jung, Andreas R. Thomsen, Tanja N. Hartmann, Justus Duyster, Martin J. Hug, Kareem A. Azab, Manfred Jung, Ralph Wäsch & Monika Engelhardt. (2022) Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma. Journal of Cancer Research and Clinical Oncology 148:5, pages 1045-1055.
Crossref
Crossref
Heather Fairfield, Samantha Costa, Carolyne Falank, Mariah Farrell, Connor S. Murphy, Anastasia D’Amico, Heather Driscoll & Michaela R. Reagan. (2021) Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes. Frontiers in Oncology 10.
Crossref
Crossref
Nicola Giuliani, Federica Costa & Valentina Marchica. 2021. Management of Bone Disease and Kidney Failure in Multiple Myeloma. Management of Bone Disease and Kidney Failure in Multiple Myeloma
37
51
.
Gabriel M. Pagnotti, Silvia Marino, Daniela N. Petrusca, Teresita Bellido, G. David Roodman & Jesus Delgado-Calle. 2020. Encyclopedia of Bone Biology. Encyclopedia of Bone Biology
201
218
.
Z. Faraahi, M. Baud'huin, P.I. Croucher, C. Eaton & M.A. Lawson. (2019) Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells. Bone 122, pages 82-92.
Crossref
Crossref
Syed J. Mehdi, Sarah K. Johnson, Joshua Epstein, Maurizio Zangari, Pingping Qu, Antje Hoering, Frits Rhee, Carolina Schinke, Sharmilan Thanendrarajan, Bart Barlogie, Faith E. Davies, Gareth J. Morgan & Shmuel Yaccoby. (2018) Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes. British Journal of Haematology 184:4, pages 578-593.
Crossref
Crossref
Jean-Pascal Capp & Régis Bataille. (2018) Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event. Frontiers in Oncology 8.
Crossref
Crossref
Juan Guo, Youshan Zhao, Chengming Fei, Sida Zhao, Qingqing Zheng, Jiying Su, Dong Wu, Xiao Li & Chunkang Chang. (2018) Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. Cell Death & Disease 9:5.
Crossref
Crossref
J Delgado-Calle, J Anderson, M D Cregor, K W Condon, S A Kuhstoss, L I Plotkin, T Bellido & G D Roodman. (2017) Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia 31:12, pages 2686-2694.
Crossref
Crossref
Giacomina Brunetti, Maria Felicia Faienza, Graziana Colaianni, Maria Grano & Silvia Colucci. (2017) Mechanisms of Altered Bone Remodeling in Multiple Myeloma. Clinical Reviews in Bone and Mineral Metabolism 15:4, pages 151-161.
Crossref
Crossref
Jerome T. Higgs, Joo Hyoung Lee, Hong Wang, Vishnu C. Ramani, Diptiman Chanda, Cherlene Y. Hardy, Ralph D. Sanderson & Selvarangan Ponnazhagan. (2017) Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Advances 1:25, pages 2375-2385.
Crossref
Crossref
Michelle M. McDonald, Heather Fairfield, Carolyne Falank & Michaela R. Reagan. (2016) Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcified Tissue International 100:5, pages 433-448.
Crossref
Crossref
Jesus Delgado-Calle. (2017) Osteocytes and Their Messengers as Targets for the Treatment of Multiple Myeloma. Clinical Reviews in Bone and Mineral Metabolism 15:1, pages 49-56.
Crossref
Crossref
Hui Liu, Fengping Peng, Zhaoyun Liu, Fengjuan Jiang, Lijuan Li, Shan Gao, Guojin Wang, Jia Song, Erbao Ruan, Zonghong Shao & Rong Fu. (2017) CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodelling in vivo in myeloma bone disease. International Journal of Oncology 50:2, pages 631-639.
Crossref
Crossref
Nagaraju Anreddy & Lori A. Hazlehurst. (2017) Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. Journal of Cellular Biochemistry 118:1, pages 15-25.
Crossref
Crossref
Penelope D Ottewell. (2016) The role of osteoblasts in bone metastasis. Journal of Bone Oncology 5:3, pages 124-127.
Crossref
Crossref
Huan LiuZhiqiang LiuJuan DuJin HePei LinBehrang AminiMichael W. StarbuckNora NovaneJatin J. ShahRichard E. DavisJian HouRobert F. GagelJing Yang. (2016) Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Science Translational Medicine 8:353.
Crossref
Crossref
Bing Ji, Paul G. Genever & Michael J. Fagan. (2015) A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease. International Journal for Numerical Methods in Biomedical Engineering 32:3.
Crossref
Crossref
Zhiqiang Liu, Jingda Xu, Jin He, Huan Liu, Pei Lin, Xinhai Wan, Nora M. Navone, Qiang Tong, Larry W. Kwak, Robert Z. Orlowski & Jing Yang. (2015) Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget 6:33, pages 34329-34341.
Crossref
Crossref
Michaela R. Reagan, Lucy Liaw, Clifford J. Rosen & Irene M. Ghobrial. (2015) Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast. Bone 75, pages 161-169.
Crossref
Crossref
Denise Toscani, Marina Bolzoni, Fabrizio Accardi, Franco Aversa & Nicola Giuliani. (2015) The osteoblastic niche in the context of multiple myeloma. Annals of the New York Academy of Sciences 1335:1, pages 45-62.
Crossref
Crossref
Daniele Santini, Chiara Spoto, Vito Longo, Michele Iuliani, Alice Zoccoli, Salvatore Intagliata, Francesco Pantano & Franco Silvestris. 2015. Targeted Therapies for Solid Tumors. Targeted Therapies for Solid Tumors
249
266
.
Bing Ji, Paul G. Genever, Ronald J. Patton & Michael J. Fagan. (2014) Mathematical modelling of the pathogenesis of multiple myeloma‐induced bone disease. International Journal for Numerical Methods in Biomedical Engineering 30:11, pages 1085-1102.
Crossref
Crossref
Shingen Nakamura, Hirokazu Miki, Shinsuke Kido, Ayako Nakano, Masahiro Hiasa, Asuka Oda, Hiroe Amou, Keiichiro Watanabe, Takeshi Harada, Shiro Fujii, Kyoko Takeuchi, Kumiko Kagawa, Shuji Ozaki, Toshio Matsumoto & Masahiro Abe. (2013) Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib. International Journal of Hematology 98:1, pages 66-73.
Crossref
Crossref
M A Hurchla, A Garcia-Gomez, M C Hornick, E M Ocio, A Li, J F Blanco, L Collins, C J Kirk, D Piwnica-Worms, R Vij, M H Tomasson, A Pandiella, J F San Miguel, M Garayoa & K N Weilbaecher. (2012) The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 27:2, pages 430-440.
Crossref
Crossref
N Sévère, F-X Dieudonné & P J Marie. (2013) E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death & Disease 4:1, pages e463-e463.
Crossref
Crossref
Patrizia Tosi. (2013) Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement. Scientifica 2013, pages 1-12.
Crossref
Crossref
G. David Roodman. 2013. Genetic and Molecular Epidemiology of Multiple Myeloma. Genetic and Molecular Epidemiology of Multiple Myeloma
97
120
.
Vito Longo, Oronzo Brunetti, Stella D’Oronzo, Franco Dammacco & Franco Silvestris. (2012) Therapeutic approaches to myeloma bone disease: An evolving story. Cancer Treatment Reviews 38:6, pages 787-797.
Crossref
Crossref
Richard W. J. GroenWilly A. NoortReinier A. RaymakersHenk-Jan PrinsLinda AaldersFrans M. HofhuisPetra MoererJeroen F. van VelzenAndries C. BloemBerris van Kessel, Henk RozemullerEllen van BinsbergenArjan BuijsHuipin YuanJoost D. de BruijnMichel de Weers, Paul W. H. I. Parren, Jan Jacob Schuringa, Henk M. LokhorstTuna Mutis & Anton C. M. Martens. (2012) Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 120:3, pages e9-e16.
Crossref
Crossref
Hong Liu, Samantha Tamashiro, Stavroula Baritaki, Manuel Penichet, Youhua Yu, Haiming Chen, James Berenson & Benjamin Bonavida. (2012) TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target. Clinical Lymphoma Myeloma and Leukemia 12:3, pages 155-163.
Crossref
Crossref
Antonio Garcia-Gomez, Enrique M. Ocio, Edvan Crusoe, Carlos Santamaria, Pilar Hernández-Campo, Juan F. Blanco, Fermin M. Sanchez-Guijo, Teresa Hernández-Iglesias, Jesús G. Briñón, Rosa M. Fisac-Herrero, Francis Y. Lee, Atanasio Pandiella, Jesús F. San Miguel & Mercedes Garayoa. (2012) Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. PLoS ONE 7:4, pages e34914.
Crossref
Crossref
Gerrard Teoh, Yuming Chen, Kihyun Kim, Alok Srivastava, Vasant R. Pai, Sung-Soo Yoon, Cheolwon Suh & Yeo-Kyeoung Kim. (2012) Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 12:2, pages 118-126.
Crossref
Crossref
Berit Grandaunet, Silje W. Syversen, Mari Hoff, Anders Sundan, Glenn Haugeberg, Desirée van Der Heijde, Tore K. Kvien & Therese Standal. (2011) Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis. Arthritis & Rheumatism 63:3, pages 662-669.
Crossref
Crossref
Alex R. Minter, Haley Simpson, Brendan M. Weiss & Ola Landgren. (2011) Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities. Seminars in Hematology 48:1, pages 55-65.
Crossref
Crossref
G. David Roodman. (2011) Osteoblast function in myeloma. Bone 48:1, pages 135-140.
Crossref
Crossref
Angela Pennisi, Wen Ling, Xin Li, Sharmin Khan, Yuping Wang, Bart Barlogie, John D. Shaughnessy & Shmuel Yaccoby. (2010) Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone. PLoS ONE 5:12, pages e15233.
Crossref
Crossref
Shmuel Yaccoby. (2010) The role of the proteasome in bone formation and osteoclastogenesis. IBMS BoneKEy 7:4, pages 147-155.
Crossref
Crossref